Ipsen has agreed to acquire Swiss biotechnology company Memo Therapeutics AG in a transaction intended to expand its rare disease portfolio with potrapolyomavirus infection in kidney transplant recipients. The planned acquisition gives the biopharmaceutical group control of a Phase II program aimed at a condition that can compromise graft function and contribute to transplant failure. It also advances Ipsen’s strategy of using external innovation to add specialized assets in areas with substantial unmet medical need.
Transaction Terms
Under the definitive share purchase agreement, Memo shareholders are set to receive €200 million in cash at closing, calculated on a cash-free and debt-free basis. They may also receive additional development, regulatory, and sales-based payments, bringing the total potential consideration to more than €700 million. The transaction is expected to close in the third quarter of 2026, provided customary closing conditions are met, and Ipsen said the anticipated impact has already been incorporated into its full-year guidance.
Clinical Rationale
Potravitug is a monoclonal antibody designed to target the VP1 capsid protein of BK polyomavirus, blocking the virus from attaching to and entering host cells. In kidney transplant recipients, the virus can reactivate under immunosuppressive treatment, leading to BK polyomavirus-associated nephropathy, or BKPyVAN, a serious complication linked to graft dysfunction and loss. No approved targeted treatments are currently available, leaving clinicians to reduce immunosuppression to control viral replication, an approach that can increase the risk of organ rejection.
Phase II Evidence
Ipsen and Memo said results from the Phase II SAFE KIDNEY II study support moving potravitug into a pivotal Phase II/III trial later in 2026. According to the companies, the placebo-controlled trial showed stronger reductions in viral load, improvements in kidney biopsy findings, and a lower incidence of biopsy-proven BKPyVAN among patients receiving potravitug. By week 38, 24.4% of treated patients had undetectable BKPyV DNAemia, compared with 13.0% in the placebo group, while the companies reported no treatment-related serious adverse events.
Portfolio Strategy
For Ipsen, the proposed acquisition would add a mid-stage program to a rare disease franchise that sits alongside its oncology and neuroscience operations. Christelle Huguet, Ipsen’s executive vice president and head of research and development, said the company sees an opportunity to address a significant clinical gap for transplant patients while advancing a potential first-in-class therapy. Potravitug received Fast Track designation from the US Food and Drug Administration in May 2023 and orphan drug designation in the European Union in December 2025, which could support its development pathway if the program continues to generate favorable data.
Carve-Out
Before the deal closes, Memo will transfer the assets, technology, and employees not connected to potravitug into a newly formed company, Memorises Bio, which will remain owned by Memo’s existing shareholders. The carve-out includes Memo’s collaboration with CSL on recombinant polyclonal IgG technology and its DROPZYLLA antibody discovery platform, allowing the remaining business to continue work beyond the BK polyomavirus program. Memo, which is based in Schlieren near Zurich, has developed antibodies for viral infections and cancer and is backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital, and Adjuvant Capital.
The acquisition concentrates Ipsen’s investment on a defined clinical-stage treatment candidate while preserving Memo’s broader discovery and partnership activities in a separate company. Its near-term value will depend on the design and outcome of the planned pivotal trial, as well as subsequent regulatory decisions, none of which are assured. Still, the transaction underscores the commercial interest in therapies that may address a persistent post-transplant complication for which patients and physicians have no targeted approved option.